VTGN
Vistagen Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.24
close · 2026-09-14
value
97
cheaper than peers97
quality
50
stronger fundamentals50
ranked against
Biotechnology (commercial)
value
quality
159 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.44× | 98 |
| EV to EBITDA | 0.28× | 88 |
| price to sales | 4.32× | 79 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 504.9% | 91 |
| debt to equity | 3.2% | 79 |
| operating margin | -904.3% | 24 |
| return on equity | -166.5% | 15 |
4 of 4 measures available
Facts
| market cap | $11M |
| free cash flow | -$37.0M |
| employees | 41 |
| first trade | 2011-06-21 |
| next earnings | 2026-08-14 |
| fundamentals updated | 2026-09-01 |